The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Clinical Trials Confirm Secukinumab Can Effectively Treat Ankylosing Spondylitis

Clinical Trials Confirm Secukinumab Can Effectively Treat Ankylosing Spondylitis

February 29, 2016 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Science_Research_500x270UPDATE: On Jan. 15, Novartis announced that it had received two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the U.S.

You Might Also Like
  • Rheumatology Drug Updates: Abaloparatide Promising for Osteoporosis, Plus Secukinumab for Ankylosing Spondylitis
  • Abaloparatide Promising for Osteoporosis; NICE Draft Guidelines Include Secukinumab for Ankylosing Spondylitis
  • Anti-TNF Agents May Improve Clinical Symptoms of Ankylosing Spondylitis
Also By This Author
  • Updated OARSI Guideline for the Non-Surgical Management of Osteoarthritis

As this article was being edited, anti-TNF agents were the only biologics approved for the treatment of ankylosing spondylitis. A new treatment, however, is now available. Secukinumab, an anti-interleukin-17A monoclonal antibody, is currently being investigated as an alternative treatment for patients with ankylosing spondylitis. Phase 3 clinical trials are now complete, and the efficacy of secukinumab further supports the hypothesis that interleukin-17A plays an important role in the pathogenesis of ankylosing spondylitis.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dominique Baeten, MD, professor of rheumatology at the University of Amsterdam in the Netherlands, and colleagues published the results of the two Phase 3 trials (MEASURE 1 and MEASURE 2) of secukinumab online on Dec. 24, 2015, in the New England Journal of Medicine.1 The results extended the positive findings from the Phase 2 trial. The safety profile of secukinumab in the Phase 3 trials was also consistent with what had been documented previously.

MEASURE 1 took place from Nov. 9, 2011, though Jan. 21, 2013, and included 371 patients with active ankylosing spondylitis. MEASURE 2 took place from Oct. 28, 2012, through July 29, 2013, and included 219 patients with active ankylosing spondylitis. The two studies differed in that patients in the treatment arms of MEASURE 1 received intravenous secukinumab (10 mg/kg of body weight) at Weeks 0, 2 and 4. They then received subcutaneous secukinumab (150 mg or 75 mg) every four weeks starting at Week 8. In contrast, patients in the treatment arms of MEASURE 2 did not receive intravenous loading of secukinumab. Instead, they received subcutaneous secukinumab at Weeks 1, 2 and 3, and then every four weeks starting at Week 4. The primary endpoint of both studies was the proportion of patients with at least a 20% improvement in Assessment of Spondyloarthritis International Society (ASAS20) response criteria at Week 16.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Efficacy
Patients with ankylosing spondylitis who were treated with 150 mg secukinumab subcutaneously experienced significant reductions in signs and symptoms at 16 weeks. A dose of 75 mg resulted in significant improvements only in patients who had a higher intravenous loading dose (MEASURE 1). MEASURE 1 ASAS20 response rates at Week 16 were 61% (150 mg), 60% (75 mg) and 29% (placebo). In MEASURE 2, the rates were 61% (150 mg), 41% (75 mg) and 28% (placebo). In MEASURE 2, the response to 75 mg secukinumab was not statistically significant relative to placebo.

Pages: 1 2 | Single Page

Filed Under: Conditions, Spondyloarthritis Tagged With: Ankylosing Spondylitis, Anti-TNF, anti-tumor necrosis factor, secukinumab

You Might Also Like:
  • Rheumatology Drug Updates: Abaloparatide Promising for Osteoporosis, Plus Secukinumab for Ankylosing Spondylitis
  • Abaloparatide Promising for Osteoporosis; NICE Draft Guidelines Include Secukinumab for Ankylosing Spondylitis
  • Anti-TNF Agents May Improve Clinical Symptoms of Ankylosing Spondylitis
  • Benefits of Secukinumab in Ankylosing Spondylitis May Persist at 2 Years

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)